Somatostatin receptor imaging and theranostics: current practice and future prospects

S Park, AS Parihar, L Bodei, TA Hope… - Journal of Nuclear …, 2021 - Soc Nuclear Med
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms
began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET …

SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework

RA Werner, LB Solnes, MS Javadi… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Reliable standards and criteria for somatostatin receptor (SSTR) PET are still lacking. We
herein propose a structured reporting system on a 5-point scale for SSTR PET imaging, titled …

Updates to the appropriate-use criteria for somatostatin receptor PET

TA Hope - Journal of Nuclear Medicine, 2020 - Soc Nuclear Med
The guidelines of the Centers for Medicare and Medicaid Services require that appropriate-
use criteria (AUC) be reviewed yearly. The somatostatin receptor (SSTR) PET AUC was …

[HTML][HTML] The theranostic promise for Neuroendocrine Tumors in the late 2010s-Where do we stand, where do we go?

RA Werner, A Weich, M Kircher, LB Solnes… - Theranostics, 2018 - ncbi.nlm.nih.gov
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …

Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors

TA Hope, EK Bergsland, MF Bozkurt… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

[PDF][PDF] SNMMI procedure standard/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors

TA Hope, M Allen-Auerbach, L Bodei… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …

[HTML][HTML] Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments

SM Bison, MW Konijnenberg, M Melis, SE Pool… - Clinical and translational …, 2014 - Springer
Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment
for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs …

Theranostics of neuroendocrine tumors

ST Lee, HR Kulkarni, A Singh, RP Baum - Visceral medicine, 2017 - karger.com
Somatostatin receptor positron emission tomography/computed tomography using 68 Ga-
labeled somatostatin analogs is the mainstay for the evaluation of receptor status in …

Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy

D Pencharz, G Gnanasegaran… - The British Journal of …, 2018 - academic.oup.com
Theranostics and its principles: pre-treatment selection of patients who are most likely to
benefit from treatment by the use of a related, specific diagnostic test are integral to the …

[HTML][HTML] Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors

V Ambrosini, L Zanoni, A Filice, G Lamberti, G Argalia… - Cancers, 2022 - mdpi.com
Simple Summary Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors,
presenting in often challenging clinical scenarios, and require multidisciplinary discussion …